Inhibitory effect of selaginellin on high glucose-induced apoptosis in differentiated PC12 cells: Role of NADPH oxidase and LOX-1

European Journal of Pharmacology

Volumn 694, Issue 1-3, 2012, Pages 60-68

  Zhang, Wei Fang ^a   Xu, Ya Yong ^a   Xu, Kang Ping ^a   Wu, Wei Hua ^a,b   Tan, Gui Shan ^a   Li, Yuan Jian ^a   Hu, Chang Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUAIHUA MEDICAL COLLEGE   (China)

Author keywords

High glucose; Lectin like oxidized low density lipoprotein receptor 1; NADPH oxidase; PC12 cells; Reactive oxygen species; Selaginellin

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; DIMETHYL SULFOXIDE; GLUCOSE; LIPOCORTIN 5; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1 ANTIBODY; PLANT EXTRACT; PROPIDIUM IODIDE; REACTIVE OXYGEN METABOLITE; RECEPTOR ANTIBODY; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SELAGINELLIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROTECTION; CELL STRAIN; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SAUSSUREA; SAUSSUREA PULVINATA; SIGNAL TRANSDUCTION; STAINING;

ANIMALS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL DIFFERENTIATION; CELL SURVIVAL; CYCLOHEXANONES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; NADPH OXIDASE; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; TIME FACTORS; UP-REGULATION;

EID: 84867332647     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.08.011     Document Type: Article

References (32)

1. N. Azad, N.V. Emanuele, C. Abraira, W.G. Henderson, J. Colwell, S.R. Levin, F.Q. Nuttall, J.P. Comstock, C.T. Sawin, C. Silbert, and F.A. Rubino The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM) J. Diabetes Complicat. 13 1999 307 313
2. K. Chen, G.W. Plumb, R.N. Bennett, and Y. Bao Antioxidant activities of extracts from five anti-viral medicinal plants J. Ethnopharmacol. 96 2005 201 205
3. M. Chen, M. Nagase, T. Fujita, S. Narumiya, T. Masaki, and T. Sawamura Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE Biochem. Biophys. Res. Commun. 287 2001 962 968
4. M. Chen, S. Narumiya, T. Masaki, and T. Sawamura Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding Biochem. J. 355 2001 289 296
5. J.L. Edwards, A.M. Vincent, H.T. Cheng, and E.L. Feldman Diabetic neuropathy: mechanisms to management Pharmacol. Ther. 120 2008 1 34
6. L.A. Greene, and A.S. Tischler Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor Proc. Nat. Acad. Sci. U.S.A 73 1976 2424 2428
7. M. Heather West Greenlee, E. Uemura, S.L. Carpenter, R.T. Doyle, and J.E. Buss Glucose uptake in PC12 cells: GLUT3 vesicle trafficking and fusion as revealed with a novel GLUT3-GFP fusion protein J. Neurosci. Res. 73 2003 518 525
8. C. Hu, and J. Mehta Biology of LOX-1 in relation to atherogenesis Future Lipidol. 3 2008 689 696
9. D.J. Jiang, S.J. Jia, Z. Dai, and Y.J. Li Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells J. Mol. Cell Cardiol. 40 2006 529 539
10. K. Koshimura, J. Tanaka, Y. Murakami, and Y. Kato Involvement of nitric oxide in glucose toxicity on differentiated PC12 cells: prevention of glucose toxicity by tetrahydrobiopterin, a cofactor for nitric oxide synthase Neurosci. Res. 43 2002 31 38
11. H.S. Lee, S.M. Son, Y.K. Kim, K.W. Hong, and C.D. Kim NAD(P)H oxidase participates in the signaling events in high glucose-induced proliferation of vascular smooth muscle cells Life Sci. 72 2003 2719 2730
12. L. Li, T. Sawamura, and G. Renier Glucose enhances endothelial LOX-1 expression: role for LOX-1 in glucose-induced human monocyte adhesion to endothelium Diabetes 52 2003 1843 1850
13. L. Li, T. Sawamura, and G. Renier Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation Circ. Res. 94 2004 892 901
14. J.L. Mehta, M. Khaidakov, P.L. Hermonat, S. Mitra, X. Wang, G. Novelli, and T. Sawamura LOX-1: a new target for therapy for cardiovascular diseases Cardiovasc. Drug Ther. 25 2011 495 500
15. S. Mitra, T. Goyal, and J.L. Mehta Oxidized LDL, LOX-1 and atherosclerosis Cardiovasc. Drug Ther. 25 2011 419 429
16. S. Penugonda, S. Mare, G. Goldstein, W.A. Banks, and N. Ercal Effects of N-acetylcysteine amide (NACA), a novel thiol antioxidant against glutamate-induced cytotoxicity in neuronal cell line PC12 Brain Res. 1056 2005 132 138
17. N.K. Sah, S.N. Singh, S. Sahdev, S. Banerji, V. Jha, Z. Khan, and S.E. Hasnain Indian herb 'Sanjeevani' (Selaginella bryopteris) can promote growth and protect against heat shock and apoptotic activities of ultra violet and oxidative stress J. Biosci. 30 2005 499 505
18. A.M. Sharifi, H. Eslami, B. Larijani, and J. Davoodi Involvement of caspase-8, -9, and -3 in high glucose-induced apoptosis in PC12 cells Neurosci. Lett. 459 2009 47 51
19. A.M. Sharifi, S.H. Mousavi, M. Farhadi, and B. Larijani Study of high glucose-induced apoptosis in PC12 cells: role of bax protein J. Pharmacol. Sci. 104 2007 258 262
20. L.A. Sombers, T.L. Colliver, and A.G. Ewing Differentiated PC12 cells: a better model system for the study of the VMAT's effects on neuronal communication Ann. N. Y. Acad. Sci. 971 2002 86 88
21. A. Taye, A.H. Saad, A.H. Kumar, and H. Morawietz Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose Eur. J. Pharmacol. 627 2010 42 48
22. D.R. Tomlinson, and N.J. Gardiner Glucose neurotoxicity Nat. Rev. Neurosci. 9 2008 36 45
23. L. Tie, Y. Xu, Y.H. Lin, X.H. Yao, H.L. Wu, Y.H. Li, Z.F. Shen, H.M. Yu, and X.J. Li Down-regulation of brain-pancreas relative protein in diabetic rats and by high glucose in PC12 cells: prevention by calpain inhibitors J. Pharmacol. Sci. 106 2008 28 37
24. D.R. Tomlinson, and N.J. Gardiner Glucose neurotoxicity Nat. Rev. Neurosci. 9 2008 36 45
25. A.M. Vincent, J.M. Hayes, L.L. McLean, A. Vivekanandan-Giri, S. Pennathur, and E.L. Feldman Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1 Diabetes 58 2009 2376 2385
26. A.M. Vincent, L.L. McLean, C. Backus, and E.L. Feldman Short-term hyperglycemia produces oxidative damage and apoptosis in neurons FASEB J. 19 2005 638 640
27. P.C. Waldmeier, and W.G. Tatton Interrupting apoptosis in neurodegenerative disease: potential for effective therapy? Drug Discovery Today 9 2004 210 218
28. C.J. Wang, C.P. Hu, K.P. Xu, G.S. Tan, and Y.J. Li Effects of selaginellin on homocysteine-induced senescence in human umbilical vein endothelial cells J. Cardiovasc. Pharmacol. 55 2010 560 566
29. C.J. Wang, C.P. Hu, K.P. Xu, Q. Yuan, F.S. Li, H. Zou, G.S. Tan, and Y.J. Li Protective effect of selaginellin on glutamate-induced cytotoxicity and apoptosis in differentiated PC12 cells Naunyn-Schmiedeberg's Arch. Pharmacol. 381 2010 73 81
30. N. Yamamoto, M. Toyoda, M. Abe, T. Kobayashi, K. Kobayashi, M. Kato, M. Miyauchi, M. Kimura, T. Umezono, and D. Suzuki Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy Intern. Med. 48 2009 189 194
31. M. Yan, J.L. Mehta, W. Zhang, and C. Hu LOX-1, oxidative stress and inflammation: a novel mechanism for diabetic cardiovascular complications Cardiovasc. Drug Ther. 25 2011 451 459
32. R. Yoshimoto, Y. Fujita, A. Kakino, S. Iwamoto, T. Takaya, and T. Sawamura The discovery of LOX-1, its ligands and clinical significance Cardiovasc. Drug Ther. 25 2011 379 391